Prostate Risk Or Radiology Assessment Non-inferiority Design, Upfront MRI or Risk Calculator in Men With Suspected Prostate Cancer (PRORAND)

March 12, 2026 updated by: Norwegian University of Science and Technology

PRORAND - Prostate Risk or Radiology Assessment Non-inferiority Design, a Comparison of Upfront MRI vs Risk Calculator in Men With Suspected Prostate Cancer

Thousands of men take a PSA test to investigate whether they have prostate cancer every year. For the vast majority, the test is normal and further investigations are not necessary. In others, the test is sufficiently elevated that men are referred for further investigations. Most men with an elevated PSA are offered an MRI examination of the prostate gland, and for some, a tissue sample of the prostate is also recommended if the suspicion of cancer is high enough. Although this comprehensive investigation reveals most clinically significant , or dangerous cases of cancer, many indolent, or "harmless" cancer cases are also detected, which would not have caused the man any harm during his lifetime (approximately 20% of all prostate cancer diagnoses diagnosed in current clinical practive). Cancer treatment is not recommended for such cases, but for many men, the diagnosis and subsequent follow-up can cause him and his family anxity and concern. In addition, prostate biopsies are unpleasant for the patient and the investigation process is resource-intensive for both the man and the health care service.

Risk stratification uses machine learning methods to better identify the men who require further investigations with MRI and tissue samples. In this project, the investigators investigate whether the best risk stratification tools are non-inferior in detecting clinically significant prostate cancer compared to current practice, and whether they lead to fewer tissue samples, MRI scans, less health anxiety, and better cost-effectiveness.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Background Prostate cancer (PCa) is the most common non-skin cancer among men. Most PCa cases are identified after an elevated prostate-specific antigen (PSA) level has been identified on blood testing. In most men this leads to a hospital referral, magnetic resonance imaging (MRI) of the prostate, and biopsy (tissue sampling) of the prostate in men where MRI is suggestive of a prostate cancer.

Although the PSA-test is the main method for identifying men who have prostate cancer, the test has low specificity, meaning that many men with an elevated PSA-level do not harbour PCa that will cause the man harm within his lifetime. In current clinical practice, such "false" PSA elevations can be difficult to distinguish from the "true" elevations found in men with clinically significant PCa (csPCa, Gleason >3+3) and therefore still lead to an MRI, and in many cases even a biopsy procedure is necessary to exclude csPCa.

Multivariable risk stratification uses the statistical methods of machine learning to quantify a man's probability of having prostate cancer based on other information that is available about the patient, which is known to affect the likelihood of him having prostate cancer. The aim of such stratification is to improve the identification of men who are likely to have prostate cancer, beyond the capacity of the unspecific PSA test, with its many false positives. This in order to improve identification of men who actually need further diagnostic testing, and to better distinguish these men from those men where the probability of significant disease is so low that further investigations can safely be omitted, without missing cases of significant disease.

Although such risk stratification tools have previously been developed, are readily available, and in retrospective studies have been demonstrated to reduce unnecessary MRIs and biopsies considerably, clinical uptake continues to be low due to the lack of prospective trials demonstrating efficacy and safety. As a result, at present, almost all men referred with a suspicion of prostate cancer undergo MRI and subsequent clinical assessment for biopsy. In health care settings where PCa-screening is implemented, as is a stated goal in the EU Council cancer screening guidelines, the number of men requiring diagnostic work-up will likely increase dramatically in ensuing years.

Knowledge gaps The risk calculators (RCs) stemming from the European Randomised Study of Screening for Prostate Cancer (ERSPC) are the currently best known and most utilised multivariable risk stratification tools. Their use has been retrospectively validated in multiple studies. All presently available development, and almost all validating studies are, however, hampered by their retrospective design and varying size which presently hinder widespread clinical implementation of this promising new method. In the only prospective study known to us, 47% of MRI investigations could be avoided compared with today's practice of performing an MRI in all men referred with an elevated PSA (>3ng/ml). However, this study was not designed to answer the primary research question of the present proposal, namely whether this RC approach gives csPCa detection that is non-inferior to performing an MRI in all referred men. As a result, although multivariable risk stratification of men with suspected PCa holds promise, whether the method gives non-inferior cancer detection to current practice represents a key knowledge gap which presently limits its implementation.

Study aims The primary objective of the current proposal is to perform the first prospective, adequately powered investigation of whether risk stratification using the risk stratification calculators from the European Randomised Study of Screening for Prostate Cancer study gives non-inferior detection of clinically significant prostate cancer compared with performing an MRI in all men referred with a suspicion of prostate cancer.

How clinical decision-making in men suspected of harbouring PCa affects men's health-related quality of life also has not been thoroughly investigated. And similarly, whether multivariable risk stratification is in fact cost-efficient compared with an MRI-all approach has not been conclusively determined in a prospective, clinical trial. The secondary aims of the study are to examine how the decision of whether to perform biopsy affects the health-related quality of life of men who undergo such consideration, and to prospectively determine the cost-efficiency of performing multivariable risk stratification, compared with performing an MRI in all men referred with a suspicion of prostate cancer.

Study Type

Interventional

Enrollment (Estimated)

1016

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • more than 10 years remaining life expectancy
  • Suspected localized prostate cancer
  • Suspicious DRE (cT2)
  • PSA 3-20 ng/ml

Exclusion Criteria:

  • cT3 and/or cT4 (on DRE)
  • PSA >20 ng/ml
  • Prior diagnosis of prostate cancer
  • Contraindications to MRI or to prostate biopsy
  • Medications known to affect serum PSA levels

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Upfront MRI and Multivariable risk assessment in all men
Single group
Device: European Study of screening for prostate cancer risk calculator
The ERSPC RCs are the currently best known and most utilised multivariable PCa risk stratification tools. All participating men undergo risk stratification by ERSPC RCs to determine need for MRI and for biopsy.
Other Names:
  • https://www.prostatecancer-riskcalculator.com/
  • Rotterdam prostate cancer risk calculator

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Detection of clinically significant prostate cancer
Time Frame: During the initial diagnostic work-up (up to 6 weeks)

The study examines whether the risk calculator strategy gives non-inferior detection of csPCa compared with performing an MRI upfront in all men.

csPCa defined as International society of Urological pathology grade group (ISUP GG) >1.
During the initial diagnostic work-up (up to 6 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Detection of clinically insignificant prostate cancer
Time Frame: During the initial diagnostic work-up (up to 6 weeks)
The investigators will compare the number of patients with low grade (ISUP GG 1) prostate cancer detected by the upfront MRI vs upfront RC strategies
During the initial diagnostic work-up (up to 6 weeks)
Numbers of prostate biopsy sessions required
Time Frame: 1 year after completion of inclusion
Determine the number of prostata biopsy sessions required by the upfront MRI vs upfront RC strategies
1 year after completion of inclusion
Numbers of prostate MRIs required
Time Frame: 1 year after completion of inclusion
Determine the number of prostate MRI scans required by the upfront MRI vs upfront RC strategies
1 year after completion of inclusion
Quality of life effect of decision to perfrom prostate biopsy
Time Frame: 1 year after study inclusion is completed

The investigators assess the health-related quality of life effect of the decision to perform biopsy in men referred with suspected prostate cancer.

Questionnaire that will be used to assess participants' quality of life: EORTC (European Organisation for Research and Treatment of Cancer) QLQ-C30 form. The EORTC QLQ-C30 (v3.0) scores 30 items into 5 functional scales, 9 symptom scales/items, and global health status (0-100 range). Higher scores indicate better functioning/QoL but worse symptoms.
1 year after study inclusion is completed
Quality of life effect of decision to perfrom prostate biopsy
Time Frame: 1 year after study inclusion is completed

The investigators assess the health-related quality of life effect of the decision to perform biopsy in men referred with suspected prostate cancer.

Questionnaire that will be used to assess participants' quality of life: IPSS (International Prostate Symptom Score). Higher scores mean more symptoms. IPSS classifies symptoms as mild (0-7), moderate (8-19), or severe (20-35)
1 year after study inclusion is completed
Quality of life effect of decision to perfrom prostate biopsy
Time Frame: 1 year after study inclusion is completed

The investigators assess the health-related quality of life effect of the decision to perform biopsy in men referred with suspected prostate cancer.

Questionnaire that will be used to assess participants' quality of life: IIEF-5 (International Index of Erectile Function) Lower IIEF-5 scores mean higher degree of erectile dysfunction
1 year after study inclusion is completed
Quality of life effect of decision to perfrom prostate biopsy
Time Frame: 1 year after study inclusion is completed

The investigators assess the health-related quality of life effect of the decision to perform biopsy in men referred with suspected prostate cancer.

Participants will be asked whether they are concerned about the possibility that they may have prostate cancer (yes/no), and about how concerned about the posibility they have cancer (no concerns, mild concerns, moderate concerns, severe concerns).
1 year after study inclusion is completed
Cost-effectiveness assessment
Time Frame: 1 year after completion of inclusion
Determine cost-effectivenes of upfront MRI vs upfront RC. The investigators will determine the incremental cost-effectiveness ratio (ICER) and the net monetary benefit (NMB)
1 year after completion of inclusion
Perilesional biopsy results
Time Frame: During the initial diagnostic work up (up to 6 weeks)
Targeted biopsies will be taken from PI-RADS 3-5 lesions on MRI. Additional biopsies are to be taken from the area of prostate surrounding the lesion in the prostate seen on MRI, as per current European Urological Association guidelines. The study will assess the value of perilesional biopsies by recording the detection of prostate cancer in such perilesional biopsies.
During the initial diagnostic work up (up to 6 weeks)
Quality of life effect of decision to perfrom prostate biopsy
Time Frame: 1 year after study inclusion is completed.
The investigators assess the health-related quality of life effect of the decision to perform biopsy in men referred with suspected prostate cancer. Questionnaire that will be used to assess participants' quality of life: The Memorial Anxiety Scale for Prostate Cancer (MAX-PC). An 18-item, validated questionnaire designed to measure cancer-specific anxiety in men, specifically covering prostate cancer anxiety, prostate-specific antigen sampling anxiety, and fear of cancer recurrence. Higher scores mean higher degree of anxiety relating to prostate cancer and to prostate-specific antigen testing.
1 year after study inclusion is completed.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Norwegian University of Science and Technology

Collaborators

Norwegian Cancer Society

Investigators

  • Principal Investigator: Petter Davik, MD, PhD, Norwegian University of Science and Technology (NTNU)
  • Study Chair: Magnus Steigedal, PhD, Norwegian University of Science and Technology, Head of Department (IKOM)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2026

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2029

Study Registration Dates

First Submitted

December 30, 2025

First Submitted That Met QC Criteria

February 12, 2026

First Posted (Actual)

February 20, 2026

Study Record Updates

Last Update Posted (Actual)

March 16, 2026

Last Update Submitted That Met QC Criteria

March 12, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • REK KULMU 927238

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Sharing of anonmous data for scientific purposeswill be considered upon reasonable request

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Prostate Cancer

Clinical Trials on European Study of screening for prostate cancer risk calculator

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe